Invesco Ltd. Has $43.93 Million Position in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Invesco Ltd. reduced its holdings in Ultragenyx Pharmaceutical by 28.6% in the 1st quarter, now owning approximately 1.29% of the company, valued at $43.933 million.
• Several institutional investors have increased their stakes in Ultragenyx, with notable increases from Vestal Point Capital LP and Point72 Asset Management, indicating strong interest in the company.
• Analysts remain optimistic about Ultragenyx, with an average price target of $81.50 and a general rating of "Moderate Buy" from multiple equity research firms.

Invesco Ltd. reduced its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 28.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,213,282 shares of the biopharmaceutical company's stock after selling 486,474 shares during the period. Invesco Ltd. owned approximately 1.29% of Ultragenyx Pharmaceutical worth $43,933,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Deep Track Capital LP acquired a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth approximately $27,493,000. First Light Asset Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 1.1% during the 4th quarter. First Light Asset Management LLC now owns 763,607 shares of the biopharmaceutical company's stock worth $32,125,000 after purchasing an additional 8,505 shares during the last quarter. Dark Forest Capital Management LP acquired a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth approximately $459,000. Stifel Financial Corp increased its stake in Ultragenyx Pharmaceutical by 13.5% during the 4th quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company's stock worth $1,001,000 after acquiring an additional 2,835 shares during the period. Finally, Alyeska Investment Group L.P. increased its stake in Ultragenyx Pharmaceutical by 23.1% during the 4th quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock worth $60,570,000 after acquiring an additional 269,733 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Canaccord Genuity Group lowered their price objective on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Guggenheim restated a "buy" rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. William Blair assumed coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective on the stock. Cantor Fitzgerald lowered their price objective on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 6th. Finally, Wedbush lowered their price objective on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research note on Monday, July 14th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $81.50.

Insiders Place Their Bets

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the sale, the director owned 15,344 shares in the company, valued at $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Stock Up 1.1%

Shares of RARE traded up $0.32 during midday trading on Friday, hitting $29.84. The company's stock had a trading volume of 340,290 shares, compared to its average volume of 1,292,260. Ultragenyx Pharmaceutical Inc. has a one year low of $25.81 and a one year high of $60.37. The company's fifty day simple moving average is $31.85 and its two-hundred day simple moving average is $35.89. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of -5.39 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. The business had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.Ultragenyx Pharmaceutical's quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.